PharmaShots Weekly Snapshots (Mar 15 – 19, 2021)

 PharmaShots Weekly Snapshots (Mar 15 – 19, 2021)

PharmaShots Weekly Snapshots (Mar 15 – 19, 2021)

Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases

Published: Mar 19, 2021 | Tags: Takeda, Collaborates, Anima, Discover, Develop, mRNA Translation Modulators, Neurological Diseases

Kiniksa’s Arcalyst (rilonacept) Receives the US FDA’s Approval for the Treatment of Pericarditis

Published: Mar 19, 2021 | Tags: Kiniksa, Arcalyst (rilonacept), Receives, US, FDA, Approval,  Treatment, Pericarditis

Sarepta Therapeutics Report Results of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E

Published: Mar 19, 2021 | Tags: Sarepta Therapeutics, Report, Results, SRP-9003, Treatment, Limb-Girdle Muscular Dystrophy Type 2E

Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates

Published: Mar 19, 2021 | Tags: Pfizer, Signs, WW, License Agreement, Pyxis, Develop, Commercialize, Two ADC Candidates

Boston Signs Out-License and Option Agreement with GSK to Advance Two Programs for Oncology and CNS Disorders

Published: Mar 19, 2021 | Tags: Boston, Signs, Out-License, Option Agreement, GSK, Advance, Two Programs, Oncology, CNS Disorders

Gilead Expands its Collaboration with Novo Nordisk to Evaluate Triple Combination Regimen for Compensated Cirrhosis (F4) due to NASH

Published: Mar 19, 2021 | Tags: Gilead, Expands, Collaboration, Novo Nordisk, Evaluate, Triple Combination Regimen, Compensated, Cirrhosis (F4), NASH

GSK Initiates P-III Study of GSK3511294 (GSK’294) for the Treatment of Severe Asthma

Published: Mar 18, 2021 | Tags: GSK, Initiates, P-III, Study, GSK3511294 (GSK’294), Treatment, Severe Asthma

Merck’s Keytruda (pembrolizumab) Receives the EC’s Approval in Adults & Pediatric patients with R/R cHL

Published: Mar 18, 2021 | Tags: Merck, Keytruda (pembrolizumab), Receives, EC, Approval, Adults & Pediatric patients, R/R cHL

FSD Pharma Signs a License Agreement with Innovet to Develop Veterinary Drugs for Gastro-Intestinal Diseases in Dogs and Cats

Published: Mar 18, 2021 | Tags: FSD Pharma, Signs, License Agreement, Innovet, Develop, Veterinary Drugs, Gastro-Intestinal, Diseases

Merck Signs a Five-Year Agreement with M2GEN to Advance Cancer Therapies

Published: Mar 18, 2021 | Tags: Merck, Signs, Five-Year, Agreement, M2GEN, Advance, Cancer Therapies

WuXi Biologics to Acquire Pfizer’s Biologics Manufacturing Facilities in China

Published: Mar 18, 2021 | Tags: WuXi Biologics, Acquire, Pfizer, Biologics, Manufacturing Facilities, China

Merck Collaborates with Amathus Therapeutics to Develop Treatments for Neurodegenerative Diseases

Published: Mar 18, 2021 | Tags: Merck, Collaborates, Amathus Therapeutics, Develop, Treatments, Neurodegenerative Diseases

NCCN Collaborates with Pfizer for New Biosimilars Research Projects in Oncology

Published: Mar 17, 2021 | Tags: NCCN, Collaborates, Pfizer, New, Biosimilars, Research Projects, Oncology

Johnson & Johnson Report Long-Term Data of Tremfya (guselkumab) in P-III DISCOVER-2 Study for Active Psoriatic Arthritis

Published: Mar 17, 2021 | Tags: Johnson & Johnson, Report, Long-Term Data, Tremfya (guselkumab), P-III DISCOVER-2, Study, Active, Psoriatic Arthritis

FibroGen Initiates P-III LELANTOS-2 Study of Pamrevlumab for Duchenne Muscular Dystrophy

Published: Mar 17, 2021 | Tags: FibroGen, Initiates, P-III LELANTOS-2, Study, Pamrevlumab,  Duchenne Muscular Dystrophy

Sanofi Out Licenses Two Sickle Cell Disease Programs to GBT for $353M

Published: Mar 17, 2021 | Tags: Sanofi, Out Licenses, Two Sickle Cell Disease Programs, GBT, $353M

Lilly Reports Results of Mirikizumab in P-III LUCENT-1 Induction Study for Ulcerative Colitis

Published: Mar 17, 2021 | Tags: Lilly, Reports, Results, Mirikizumab, P-III LUCENT-1, Induction Study, Ulcerative Colitis

GSK and Medicago Initiate P-III Trial for Adjuvanted COVID-19 Vaccine Candidate

Published: Mar 17, 2021 | Tags: GSK and Medicago, Initiate, P-III Trial, Adjuvanted, COVID-19 Vaccine Candidate

Merck Reports the US FDA’s Acceptance of NDA for Priority Review of Belzutifan (MK-6482) to Treat Patients with Von Hippel-Lindau Disease Associated RCC

Published: Mar 16, 2021 | Tags: Merck, Reports, US, FDA, Acceptance, NDA, Priority Review,  Belzutifan (MK-6482),Treat, Patients, Von Hippel-Lindau Disease Associated RCC

Genentech Reports Two-Year Data of Evrysdi (risdiplam) for People with Type 2 or Type 3 SMA

Published: Mar 16, 2021 | Tags: Genentech, Reports, Two-Year Data, Evrysdi (risdiplam), People, Type 2 or Type 3 SMA

Roche Launches Cobas SARS-CoV-2 Variant Test to Detect Emerging Coronavirus Mutations

Published: Mar 16, 2021 | Tags: Roche, Launches, Cobas SARS-CoV-2 Variant Test, Detect, Emerging, Coronavirus, Mutations

Novartis and Molecular Partners Report Inclusion of Ensovibep (MP0420) in NIH-Sponsored ACTIV-3 Trial for the Treatment of COVID 19

Published: Mar 16, 2021 | Tags: Novartis and Molecular Partners, Report, Inclusion, Ensovibep (MP0420), NIH-Sponsored, ACTIV-3 Trial, Treatment, COVID 19

Gilead Collaborates with Merck to Jointly Develop and Commercialize Lenacapavir + Islatravir for HIV

Published: Mar 16, 2021 | Tags: Gilead, Collaborates, Merck, Jointly, Develop, Commercialize, Lenacapavir, Islatravir, HIV

Takeda Signs a License Agreement with Genevant to Develop Novel Nucleic Acid Therapeutics for Liver Fibrosis

Published: Mar 16, 2021 | Tags: Takeda, Signs, License Agreement, Genevant, Develop, Novel, Nucleic Acid, Therapeutics, Liver Fibrosis

BioXcel’s BXCL501 Receives the US FDA’s Breakthrough Therapy Designation for Acute Treatment of Agitation Associated with Dementia

Published: Mar 15, 2021 | Tags: BioXcel, BXCL501, Receives, US, FDA, Breakthrough Therapy Designation, Acute, Treatment, Agitation, Associated, Dementia

Cardinal Health to Divest its Cordis Business to Hellman & Friedman for $1B

Published: Mar 15, 2021 | Tags: Cardinal Health, Divest, Cordis Business, Hellman & Friedman, $1B

BMS Collaborates with Aveo to Evaluate Opdivo (nivolumab) + Fotivda (tivozanib) in P-III Study for Relapsed Renal Cell Carcinoma

Published: Mar 15, 2021 | Tags: BMS, Collaborates, Aveo, Evaluate, Opdivo (nivolumab), Fotivda (tivozanib), P-III Study, Relapsed Renal Cell Carcinoma

Roche to Acquire GenMark Diagnostics for $1.8B

Published: Mar 15, 2021 | Tags: Roche, Acquire, GenMark Diagnostics, $1.8B

Regeneron and Sanofi Report Results of Libtayo (cemiplimab) in P-III Trial for Cervical Cancer

Published: Mar 15, 2021 | Tags: Regeneron and Sanofi, Report, Results, Libtayo (cemiplimab), P-III Trial, Cervical Cancer

Eli Lilly Report Result of Donanemab in P-II TRAILBLAZER-ALZ Study for Alzheimer’s Disease

Published: Mar 15, 2021 | Tags: Eli Lilly, Report, Result, Donanemab, P-II TRAILBLAZER-ALZ, Study, Alzheimer’s Disease

Related Post: PharmaShots Weekly Snapshots (Mar 08 – 12, 2021)

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post